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Background: Patients with heart failure (HF) with concomitant
ischemic heart disease (IHD) have not been well characterized. We
examined survival of patients with ischemic HF syndrome (IHFS),
defined as presentation with acute HF and concomitant features sug-
gestive of IHD.
Methods: Patients were included if they presented with acute HF to
hospitals in Ontario, Canada. IHD was defined by any of the following
criteria: angina/chest pain, prior myocardial infarction (MI), or troponin
elevation that was above the upper limit of normal (mild) or suggestive
of cardiac injury. Deaths were determined after hospital presentation.
Results: Of 5353 patients presenting with acute HF, 4088 (76.4%)
exhibited features of IHFS. Patients with IHFS demonstrated a higherReceived for publication December 20, 2019. Accepted February 19, 2020.
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Contexte : Les patients presentant une insuffisance cardiaque et une
cardiopathie ischemique (CI) concomitante ne sont pas bien
caracterises. Nous avons examine les donnees sur la survie de patients
atteints d’un syndrome d’insuffisance cardiaque ischemique (SICI),
caracterise par la presence d’une insuffisance cardiaque aiguë et de
manifestations concomitantes evoquant une CI.
Methodologie : Les donnees examinees concernaient des patients
atteints d’insuffisance cardiaque aiguë reçus en consultation dans des
hôpitaux de l’Ontario, au Canada. Un patient etait repute atteint de CI
s’il repondait à l’un des critères suivants : angine/douleur thoracique,
antecedents d’infarctus du myocarde (IM) ou elevation de la concen-
tration de troponine se situant au-delà de la limite superieure de laHeart failure (HF) is a major public health issue with a current high, with up to 50% of those diagnosed with HF dying
prevalence of more than 26 million people affected world-
wide, a 20% lifetime risk of developing HF, and increasing
numbers of people living with the disease.1-3 Mortality is alsowithin 5 years.4 HF is also responsible for substantial
healthcare costs, and a major contributor to the costs and
morbidity of HF is acute HF decompensation, which often
leads to hospital admission. Further, each decompensation
leading to HF hospitalization is associated with an incremental
risk of subsequent death.5
Prior studies have highlighted that patients with HF with
concomitant ischemic heart disease (IHD) are at heightened
risk for adverse events.6 However, outcomes in this hetero-
geneous group of patients have not been fully characterized in
the acute setting. Generally, the importance of IHD in pa-
tients with HF is assessed by comparing outcomes in those
with an ischemic etiology or history of myocardial infarctionThis is an open access article under the CC BY-NC-ND license (http://
rate of 30-day (hazard ratio [HR], 1.89; 95% confidence interval [CI],
1.33-2.68) and 1-year death (HR, 1.16, 95% CI, 1.00-1.35) compared
with those with nonischemic HF. Troponin elevation demonstrated the
strongest association with mortality. Mildly elevated troponin was
associated with increased hazard over 30-day (HR, 1.77; 95% CI, 1.12-
2.81) and 1-year (HR, 1.63; 95% CI, 1.38-1.93) mortality. Troponins
indicative of cardiac injury were associated with increased hazard of
death over 30 days (HR, 2.33; 95% CI, 1.63-3.33) and 1 year (HR,
1.40; 95% CI, 1.21-1.61). The association between elevated troponin
and higher mortality at 30 days was similar in left ventricular ejection
fraction subcategories of HF with reduced ejection fraction, HF with
mildly reduced ejection fraction, or HF with preserved ejection fraction
(P interaction ¼ 0.588). After multivariable adjustment, prior MI and
angina were not associated with higher mortality risk.
Conclusions: In acute HF, elevated troponin, but not prior MI or angina,
was associated with a higher risk of 30-day and 1-year mortality irre-
spective of left ventricular ejection fraction.
normale (cas leger) ou evoquant une lesion cardiaque. La
determination des decès a ete effectuee en aval des consultations
hospitalières.
Resultats : Parmi 5 353 patients atteints d’insuffisance cardiaque
aiguë reçus en consultation, 4 088 (76,4 %) presentaient des ca-
racteristiques de SICI. Chez les patients atteints d’un SICI, un taux plus
eleve de mortalite à 30 jours (rapport des risques instantanes [RRI] :
1,89, intervalle de confiance [IC] à 95 % : 1,33-2,68) et à 1 an (RRI :
1,16, IC à 95 % : 1,00-1,35) a ete note comparativement aux patients
atteints d’insuffisance cardiaque non ischemique. L’elevation de la
concentration de troponine presentait la plus forte association avec la
mortalite. Une legère elevation de la concentration de troponine se
trouvait associee à un risque accru de mortalite à 30 jours (RRI : 1,77,
IC à 95 % : 1,12-2,81) et à 1 an (RRI : 1,63, IC à 95 % : 1,38-1,93). Les
concentrations de troponine temoignant de lesions cardiaques etaient
associees à une augmentation du risque de mortalite à 30 jours (RRI :
2,33, IC à 95 % : 1,63-3,33) et à 1 an (RRI : 1,40, IC à 95 % : 1,21-
1,61). L’association entre une concentration elevee de troponine et
une augmentation du taux de mortalite à 30 jours etait semblable
dans les sous-categories d’insuffisance cardiaque avec fraction
d’ejection ventriculaire gauche reduite, legèrement reduite ou
preservee (p ¼ 0,588 pour l’interaction). Après correction multivariee,
les antecedents d’IM et d’angine n’etaient pas associes à un risque
accru de mortalite.
Conclusions : Dans un contexte d’insuffisance cardiaque aiguë,
l’elevation de la concentration de troponine etait associee à un risque
plus eleve de mortalite à 30 jours et à 1 an independamment de la
fraction d’ejection ventriculaire gauche; les antecedents d’IM ou
d’angine ne l’etaient toutefois pas.
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Volume 2 2020(MI). However, some patients may present with symptomatic
myocardial ischemia, troponin elevation, or both, and out-
comes in these subsets of patients are less well characterised,
especially when they decompensate.
Although angina in patients with HF studied in an
ambulatory clinical trial setting was associated with increased
risk of cardiovascular events, the frequency and impact of
angina in patients presenting with acute HF are unknown.7 In
addition, there are conflicting reports about the relationship
between troponin, a biomarker of myocardial injury, and
outcomes in acute HF. Higher troponin was associated with
higher risk in the Serelaxin, Recombinant Human Relaxin,
for Treatment of Acute Heart Failure (RELAX-AHF) trial,
whereas no such relationship was observed in Acute Study of
Clinical Effectiveness of Nesiritide in Decompensated Heart
Failure (ASCEND-HF).8,9
The relationship between IHD and outcomes may be
modified by left ventricular ejection fraction (LVEF).10 In the
Framingham Heart Study, coronary heart disease was a more
common cause of death in those with HF with reduced
ejection fraction (HFrEF), compared with those with HF with
preserved ejection fraction (HFpEF).10 In the present study,
we examined mortality and processes of care in patients with
ischemic HF syndrome (IHFS), defined by the presence of
anginal symptoms, prior MI, or troponin elevation compared
with those without ischemic heart syndrome. We further
examined these associations according to LVEF category:
HFrEF, HF with mildly reduced ejection fraction (HFmrEF),
and HFpEF.Methods
Patient cohort
To select cases for detailed chart abstraction, we identified
patients who (1) were aged  18 years; (2) presented to the
emergency department (ED) with a primary diagnosis of HF as
encoded in the National Ambulatory Care Reporting System;
and (3) met the clinical Framingham criteria for HF.11 Patients
were excluded if brain natriuretic peptide or NT-pro brain
natriuretic peptide levels were not indicative of HF as published
in the guidelines of the Canadian Cardiovascular Society (ie,<
100 pg/mL and < 300 pg/mL, respectively).12 We also
excluded patients who (1) had HF as a secondary diagnosis
developing after admission, (2) had an acute MI hospitalization
within 14 days before presentation, (3) were considered for
palliative treatment only or deemed “do not resuscitate” before
ED arrival, or (4) visited for a nonacute condition that could
have been managed in ambulatory care, as determined by a
Canadian Triage Acuity Score of 5.13,14
Data sources
We identified eligible patients who presented to the ED
using National Ambulatory Care Reporting System and those
subsequently hospitalized with a primary diagnosis of HF
using the Canadian Institute for Health Information
Discharge Abstract Database and the International Classifi-
cation of Diseases and Related Health Problems 10th Revision
Canada (ICD-10-CA) code I50. The Canadian Institute for
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Acute Ischemic HF and MortalityHealth Information Discharge Abstract Database and Same-
Day Surgery Databases were used to identify cardiac proced-
ures performed in hospital. The Registered Persons Database
was used to identify deaths and the Ontario Registrar General
Database provided information on cardiovascular vs non-
cardiovascular causes of death.
Sampling and data abstraction
We used stratified cluster sampling of patients admitted to
hospitals in Ontario that had an ED on-site and a yearly
volume of greater than 50 patients with acute HF per year.
Patients who presented to teaching, medium-sized (51-150
annual HF ED visits), and large (>150 annual HF ED visits)
community hospitals, from April 1, 2010, to March 31, 2013,
were eligible. If a patient had multiple visits during in this
period, only the first visit was included. Highly trained,
specialized nurse or physician abstractors collected data on
approximately 140 patients from each of 13 teaching and 30
large hospitals and approximately 50 patients from each of 27
medium-sized hospitals. Data were collected from hospital
medical records using electronic case report forms with
automated range checks, double-data entry for key variables,
and preloaded medical record numbers to minimize errors in
administrative database linkage. To ensure greater represen-
tation of patients with IHFS, we oversampled patients who
underwent cardiac catheterization (approximately one-third of
our total cohort) within 14 days of hospital admission.
Research ethics board approval was obtained from all hospitals
before data abstraction. Information was retrieved on de-
mographics, clinical characteristics (including cardiac and
noncardiac conditions), medications, and laboratory tests,
including biomarkers (eg, troponin, brain natriuretic peptide),
electrocardiogram, evaluations of left ventricle function, and
findings on invasive and noninvasive diagnostic tests. Infor-
mation on revascularization procedures was also collected.
IHD subgroups
A patient with a primary admission diagnosis of HF was
deemed, broadly, to have concomitant IHD syndrome if he/
she fulfilled any of the following criteria before index ED
presentation: (1) concurrent or prior diagnosis of MI based on
the presence of ICD-10 codes I21-I23 or atherosclerotic/IHD
(ICD-10 codes I20, I24-25) in any of the primary or sec-
ondary diagnosis codes in the previous 5 years; (2) troponin
elevation (troponin I, T, or high-sensitivity) above the upper
limit of normal (ULN) (including grey zone values of con-
ventional troponin) or exceeding the ULN on peak sample
drawn within the first 24 hours; or (3) angina within 48 hours
before admission. All other patients were classified as having
non-IHFS.
We further stratified troponin elevations as mildly elevated
or cardiac injury based on the reference ranges provided by the
clinical biochemistry laboratory at participating hospitals. The
cardiac injury threshold was defined as the troponin value
corresponding to an older definition of MI using creatine
kinase-MB and was ascertained for each participating hospi-
tal.15 Mildly elevated troponin was deemed to be present if
troponin was higher than the ULN but did not exceed the
cardiac injury threshold.15 Both mildly elevated troponin and
cardiac injury were included because prior prognostic studiesincluded both together, and a clear threshold for defining
ischemic from nonischemic etiologies has yet to be deter-
mined.16,17 To characterize the mildly elevated and cardiac
injury groups, we examined the median ratios of peak
troponin to the ULN within the initial 24 hours after emer-
gency presentation. We also stratified our analysis by LVEF
groupings where HFpEF was defined as LVEF  50%,
HFmrEF was defined as LVEF 40% to 49%, and HFrEF was
defined as LVEF < 40%.
Statistical analyses
We compared baseline characteristics between the overall
ischemic and nonischemic groups using the KruskaleWallis
test for continuous variables and chi-square test for categori-
cal variables. Multivariable Cox proportional hazards regres-
sion models were used to compare the hazard of death
between those with ischemic HF and the subcomponent
groups of the IHFS (ie, prior MI, angina, troponin elevation)
for outcomes over 30 days and 1 year. The multivariable
models were adjusted for age, sex, and type of HF (classified as
HFpEF, HFmrEF, HFrEF, or unknown ejection fraction if
left ventricular function was not measured during the index
admission or in the prior 6 months). Multivariable models
were also adjusted for components of the Emergency Heart
Failure Mortality Risk Grade18 and other prognostic factors,
including diabetes, hypertension, cerebrovascular disease, de-
mentia, chronic obstructive pulmonary disease, hepatic
cirrhosis, prior percutaneous coronary intervention or coro-
nary artery bypass graft surgery, respiratory rate, haemoglobin
levels, sodium concentration, left bundle branch block or
paced rhythm on 12-lead electrocardiogram, atrial fibrillation/
flutter, and QRS duration. To account for clustering of pa-
tients within hospitals, robust standard errors were obtained
when using the Cox model. Cumulative incidence curves for
mortality were compared using Gray’s test. Statistical signifi-
cance was determined as a 2-tailed P value < 0.05. Analyses
were performed using SAS version 9.4 (SAS Institute, Inc.,
Cary, NC).Results
Patient characteristics
Initially, 6846 patients were evaluated (flow diagram in
Fig. 1). After exclusions, there were 4088 patients with IHFS,
of whom 65.8% had troponin above the ULN (troponin
positive), 45.0% had angina, and 52.7% had a prior MI
(Fig. 2). Baseline characteristics are shown in Table 1. Patients
with HF with IHFS were more likely to be male, were more
often transported via emergency medical services, and had
more comorbid diabetes, hypertension, cerebrovascular dis-
ease, and peripheral artery disease. Nonischemic patients more
often had atrial fibrillation or flutter. Echocardiographic
findings demonstrated that patients in the ischemic group
more often had a lower LVEF (ie, had HFrEF or HFmrEF)
compared with the nonischemic group. Cohort characteristics
stratified by angina, prior MI, and troponin elevation are
shown in Supplemental Tables S1-S3. The ratios of peak
troponin to ULN are shown for troponin I, high-sensitivity
troponin I, troponin T, and high-sensitivity troponin T in
Figure 1. Patient flow diagram. BNP, B-type natriuretic peptide; CTAS, Canadian Triage Acuity Score; DNR, do not resuscitate; ED, emergency
department; HF, heart failure; MI, myocardial infarction.
n=972
n=580n=479
n=484
n=536
n=696
n=341
Troponin Posive
Angina/Chest Pain Prior MI
Total Ischemic HF cohort: n= 4088
Figure 2. Venn diagram of ischemic HF cohort defining characteris-
tics: prior MI, angina/chest pain, and troponin positivity. HF, heart
failure; MI, myocardial infarction.
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normal, mildly elevated, and cardiac injury. Interquartile
ranges of these ratios are shown in Supplemental Table S4.
Those with mildly elevated troponin had values that were
approximately 2-fold higher, whereas cardiac injury was 3 to 4
times higher than the ULN independent of the type of
troponin test used.
Thirty-day mortality
The 30-day mortality was 6.9% in patients with ischemic
HF and 3.9% in patients with nonischemic HF. After
adjusting for age and sex, the hazard ratio (HR) for death over
30 days in ischemic HF was 1.92 (95% confidence
interval [CI], 1.46-2.55) compared with nonischemic HF
(P < 0.001). The HR was similar after multivariable adjust-
ment: 1.89 (95% CI, 1.33-2.68; P < 0.001). When troponin
elevation, angina, and prior MI were entered into the multi-
variable model in place of any ischemia, only troponin was
independently associated with a higher rate of mortality
over 30 days. The adjusted HR was 2.19 (95% CI, 1.55-3.10;
P < 0.001) for elevated vs normal troponin and 0.87 (95%
CI, 0.67-1.12; P ¼ 0.269) for angina, and the HR was 0.92
(95% CI, 0.74-1.14; P ¼ 0.433) for prior MI vs no prior MI.
There was no significant interaction for 30-day mortality
between LVEF categories (ie, HFrEF, HFmrEF, or HFpEF)
and troponin elevation considered as a binary variable
(interaction P value ¼ 0.588). There was also no significant
interaction between LVEF category and chest pain (interac-
tion P value ¼ 0.400) or prior MI (interaction P value ¼
0.612) for the outcome of 30-day mortality.
One-year mortality
One-year mortality was 25.2% in patients with IHFS and
23.6% in patients with nonischemic HF. After adjusting
for age and sex, the HR for death over 1 year in ischemic
HF vs nonischemic patients was 1.14 (95% CI, 0.99-1.32;P ¼ 0.064). The multivariable-adjusted HR was 1.16 (95%
CI, 1.00-1.35; P ¼ 0.046). In the multivariable model,
including troponin, angina, and prior MI in the model,
the HR for 1-year mortality was 1.45 (95% CI, 1.27-1.65;
P < 0.001) for troponin elevation, 0.77 (95% CI, 0.68-0.87;
P < 0.001) for angina, and 1.13 (95% CI, 1.01-1.28;
P ¼ 0.039) for prior MI.
There was a significant interaction between LVEF category
(ie, HFrEF, HFmrEF, and HFpEF) and troponin elevation at
1-year follow-up (P ¼ 0.037). The HR for elevated troponin
(vs not elevated) was 1.50 (95% CI, 1.20-1.86; P < 0.001)
for HFrEF, 1.22 (95% CI, 0.89-1.68; P ¼ 0.225) for
HFmrEF, and 1.31 (95% CI, 1.03-1.67; P ¼ 0.028) for
HFpEF. Figure 4A-C illustrates the adjusted cumulative
incidence curves for the HFrEF, HFmrEF, and HFpEF
Table 1. Cohort characteristics
Variable, median (IQR) or n (%) IHFS (N ¼ 4088) Nonischemic (N ¼ 1265) P value
Demographic
Age, y 76 (66-83) 77 (67-85) 0.004
Men 2354 (57.6%) 568 (44.9%) < 0.001
IHFS features
Troponin positive 2688 (65.8%) 0 (0%) < 0.001
Acute angina/chest pain 1840 (45.0%) 0 (0%) < 0.001
Prior MI 2153 (52.7%) 0 (0%) < 0.001
Presenting features
Transport by EMS 1999 (48.9%) 522 (41.3%) < 0.001
Systolic BP, mm Hg 141 (122-161) 140 (123-158) 0.189
Heart rate, beats/min 90 (74-110) 90 (74-109) 0.523
Oxygen saturation, % 0.96 (0.92-0.98) 0.95 (0.92-0.98) 0.096
Comorbid conditions
Diabetes 1799 (44.0%) 493 (39.0%) 0.002
Hypertension 3166 (77.4%) 928 (73.4%) 0.003
Cerebrovascular disease 658 (16.1%) 167 (13.2%) 0.013
Peripheral artery disease 478 (11.7%) 86 (6.8%) < 0.001
Chronic pulmonary disease 875 (21.4%) 304 (24.0%) 0.049
Dementia 210 (5.1%) 94 (7.4%) 0.002
Active cancer 604 (14.8%) 204 (16.1%) 0.241
Laboratory features
Hemoglobin concentration, g/L 123 (108-139) 120 (106-135) < 0.001
White blood count, 109 cells/L 9.0 (7.1-11.6) 8.4 (6.6-10.7) < 0.001
Sodium concentration, mmol/L 138 (135-141) 138 (135-141) 0.231
Potassium concentration, mmol/L 4.2 (3.9-4.6) 4.2 (3.9-4.6) 0.914
Creatinine concentration, mmol/L 106 (82-140) 94 (74-129) < 0.001
BNP, pg/mL 466 (231-714) 432 (247-612) 0.743
ECG features
Atrial fibrillation or flutter 1093 (26.7%) 517 (40.9%) < 0.001
QRS duration, ms 104 (90-136) 96 (84-122) < 0.001
Echocardiogram, n (%)
HFrEF 1605 (39.3%) 259 (20.5%) < 0.001
HFmrEF 634 (15.5%) 121 (9.6%)
HFpEF 1132 (27.7%) 548 (43.3%)
LVEF unknown 717 (17.5%) 337 (26.6%)
BNP, brain natriuretic peptide; BP, blood pressure; EMS, emergency medical services; HF, heart failure; IQR, interquartile range; HFmrEF, heart failure with
mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; IHFS, ischemic HF syn-
drome; LVEF, left ventricular ejection fraction; MI, myocardial infarction.
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Acute Ischemic HF and Mortalitygroups, respectively, stratified by troponin positivity. The
incidence of death was higher in those with troponin elevation
(troponin positive) compared with those with normal0.5
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Figure 3. Median ratios of peak troponin to upper limit of normal
(ULN) according to classification as normal, mildly elevated, or cardiac
injury, stratified by type of troponin test. Inj, cardiac injury; mild, mildly
elevated; N, normal.troponin levels (troponin negative). Differences in mortality
rates over 1 year were significant in the HFrEF (P < 0.001)
and HFpEF (P ¼ 0.034) groups. However, there was no
significant interaction between LVEF category and chest pain
(interaction P value ¼ 0.849) or prior MI (interaction
P value ¼ 0.090).
Effect of the degree of troponin elevation as a multilevel
variable
In those with IHFS, we found that crude 30-day mortality
increased as troponin levels increased from mildly elevated to
values indicative of cardiac injury (Table 2, P trend < 0.001).
Mortality rates were significantly higher among patients with
troponins that were mildly elevated or indicative of cardiac
injury compared with normal levels, even after multivariable
adjustment (Table 2). At 30 days, the multivariable-adjusted
HR for mildly elevated troponin was 1.77 (95% CI, 1.12-
2.81) and for cardiac injury range was 2.33 (95% CI, 1.63-
3.33) compared with those with normal levels (Table 2). At 1
year, the multivariable-adjusted HR, for mildly elevated
troponin was 1.63 (95% CI, 1.38-1.93) and 1.40 (95% CI,
1.21-1.61) when troponins were indicative of cardiac injury.
When troponin was evaluated as a 3-level variable (normal,
mildly elevated, and cardiac injury), there was a significant
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Figure 4. Adjusted cumulative incidence of mortality curves for HFrEF (A), HFmrEF (B), and HFpEF (C) stratified by troponin positivity. HFmrEF, heart
failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.
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HFpEF) for the outcome of 30-day mortality (P interaction ¼
0.036). There was also a significant interaction between LVEF
category and 3-level troponin for 1-year mortality (P
interaction ¼ 0.028). Multivariable-adjusted HRs stratified by
HFrEF, HFmrEF, or HFpEF status are shown in Table 3 for
those with troponins that were mildly elevated or indicative of
cardiac injury. There was a significantly higher risk of 30-day
mortality in those with mildly elevated troponin with HFpEF
(HR, 3.25; 95% CI, 1.59-6.67; P ¼ 0.001) and higher 1-year
mortality in those with HFmrEF (HR, 1.80; 95% CI, 1.19-
2.73; P ¼ 0.006). Troponins that were mildly elevated or
indicative of cardiac injury were associated with higher risks of
death at both 30-day and 1-year time points in those with
HFrEF (Table 3).Discussion
The objective of our study was to evaluate prognosis in
acutely decompensated patients with IHFS. As a working
definition, IHFS was characterized inclusively as the presenceof anginal symptoms, history of MI, and biomarkers. We
found that those with IHFS had higher short-term and 1-year
mortality, and this risk persisted after adjustment for other
important predictors of outcome in a multivariable model.
However, the excess risk among those with ischemia was
confined to the subset of individuals with at least mildly
elevated troponin. Troponin was predictive of mortality,
irrespective of LVEF category. Angina and prior MI were not
associated with increased risk of mortality in the setting of
acute HF when entered into a multivariable model including
troponin.
There is currently no prognosis-based definition of what
constitutes ischemic etiology in HF, although patients with a
history of MI or significant coronary stenoses are typically
assigned this etiology.19,20 Several previous studies have
examined the prognostic value of chest pain and history of
coronary artery disease in stable HF, but have not studied
those presenting with an acute hospitalization. In the
Controlled Rosuvastatin Multinational Trial in Heart Failure
(CORONA) study, Badar et al.7 examined patients with
HFrEF randomized to rosuvastatin or placebo. A current or
Table 2. Associations between troponins that were mildly elevated or indicative of cardiac injury with 30-day and 1-year mortality
Outcome No troponin elevation (N ¼ 2665) Mildly elevated (N ¼ 618) Cardiac injury (N ¼ 2070) P value
Death n (%) n (%) n (%)
No. of 30-d deaths 113 (4.2%) 43 (7.0%) 175 (8.5%) < 0.001
No. of 1-y deaths 588 (22.1%) 185 (29.9%) 558 (27.0%) < 0.001
Death 30 d Adjusted HR (95% CI)
P value vs
No troponin elevation Adjusted HR (95% CI)
P value vs No
troponin elevation
Age, sex* Reference 1.65 (1.13-2.42) 0.010 2.11 (1.54-2.89) < 0.001
Age, sex, LVEFy Reference 1.69 (1.15-2.49) 0.008 2.21 (1.62-3.02) < 0.001
Multivariablez Reference 1.77 (1.12-2.81) 0.015 2.33 (1.63-3.33) < 0.001
Death 1 y Adjusted HR (95% CI) P value Adjusted HR (95% CI) P value
Age, sex* Reference 1.44 (1.21-1.70) < 0.001 1.31 (1.14-1.51) < 0.001
Age, sex, LVEFy Reference 1.45 (1.22-1.72) < 0.001 1.34 (1.17-1.54) < 0.001
Multivariablez Reference 1.63 (1.38-1.93) < 0.001 1.40 (1.21-1.61) < 0.001
CI, confidence interval; HR, hazard ratio; LVEF, left ventricular ejection fraction; MI, myocardial infarction.
* Age, sex: adjusted for age and sex.
yAge, sex, LVEF: adjusted for age, sex, HFpEF, HFmrEF, HFrEF, or LVEF unknown (LVEF within past 6 months).
zMultivariable adjusted: adjusted for age, sex, HFpEF, HFmrEF, HFrEF, or LVEF unknown (LVEF within past 6 months), arrival by emergency medical
services, triage systolic blood pressure, triage heart rate, respiratory rate, triage oxygen saturation, diabetes, hypertension, cerebrovascular disease, dementia, chronic
obstructive pulmonary disease, hepatic cirrhosis, prior percutaneous coronary intervention or coronary artery bypass graft, haemoglobin, sodium concentration,
potassium concentration, creatinine concentration, active cancer, metolazone, left bundle branch block or paced rhythm on 12-lead electrocardiogram, atrial
fibrillation/flutter, and QRS duration.
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Acute Ischemic HF and Mortalityprevious history of chest pain was associated with higher rates
of HF hospitalization and a composite ischemic outcome, but
not mortality. In a sub-study of Candesartan in Heart Failure
Assessment of Reduction in Mortality and Morbidity
(CHARM), Badar et al.21 examined patients with both
HFrEF and HFpEF randomized to candesartan or placebo. A
current or previous history of chest pain was associated with a
higher risk of ischemic outcomes, but not HF hospitalization
or death. Finally, in the Irbesartan in Patients With Heart
Failure and Preserved Ejection fraction (I-PRESERVE) trial
of patients with HFpEF randomized to irbesartan or placebo,Table 3. Multivariable-adjusted HRs in those with troponins that were mildly e
and HFpEF
Outcome/LVEF category No troponin elevation Mildly
No. of 30-d deaths n (%) n
HFrEF 29 (4.0%) 10 (4
HFmrEF 11 (3.5%) S
HFpEF 28 (2.8%) 17 (9
No. of 1-y deaths n (%) n
HFrEF 133 (18.5%) 60 (2
HFmrEF 74 (23.3%) 33 (3
HFpEF 205 (20.6%) 45 (2
Death 30-d Adjusted HR (95% CI)
HFrEF Reference 1.32 (0.75-2.33)
HFmrEF Reference 0.96 (0.11-8.48)
HFpEF Reference 3.25 (1.59-6.67)
Death 1 y Adjusted HR (95% CI)
HFrEF Reference 1.73 (1.23-2.44)
HFmrEF Reference 1.80 (1.19-2.73)
HFpEF Reference 1.32 (0.91-1.92)
Multivariable adjusted: adjusted for age, sex, arrival by emergency medical service
saturation, diabetes, hypertension, cerebrovascular disease, dementia, chronic obstru
vention or coronary artery bypass graft, haemoglobin, sodium concentration, potas
bundle branch block or paced rhythm on 12-lead electrocardiogram, atrial fibrillatio
CI, confidence interval; HFmrEF, heart failure with mid-range ejection fraction; H
reduced ejection fraction; HR, hazard ratio; LVEF, left ventricular ejection fraction;a history of coronary disease was more strongly associated with
cardiovascular and all-cause death than angina. The presence
of angina alone without coronary disease history was associ-
ated with a higher likelihood of MI or unstable angina, but
not HF hospitalization and cardiovascular or all-cause death.22
There are conflicting data on the prognostic ability of
troponin in the setting of acute HF. In the ASCEND-HF
study, troponin was not a predictor of in-hospital events
requiring treatment in a coronary intensive care unit.23 The
Value of Endothelin Receptor Inhibition With Tezosentan
in Acute Heart Failure Studies (VERITAS) trial found thatlevated or indicative of cardiac injury by LVEF category: HFrEF, HFmrEF,
elevated Cardiac injury P value
(%) n (%)
.3%) 77 (8.4%) < 0.001
C 20 (5.9%) 0.159
.8%) 22 (4.3%) < 0.001
(%) n (%)
5.8%) 221 (24.2%) 0.009
4.0%) 84 (24.6%) 0.099
6.0%) 126 (24.5%) 0.112
P value Adjusted HR (95% CI) P value
0.336 2.28 (1.42-3.67) < 0.001
0.970 1.72 (0.67-4.43) 0.257
0.001 1.69 (0.78-3.70) 0.186
P value Adjusted HR (95% CI) P value
0.002 1.44 (1.16-1.79) 0.001
0.006 1.07 (0.77-1.50) 0.677
0.149 1.31 (0.99-1.72) 0.055
s, triage systolic blood pressure, triage heart rate, respiratory rate, triage oxygen
ctive pulmonary disease, hepatic cirrhosis, prior percutaneous coronary inter-
sium concentration, creatinine concentration, active cancer, metolazone, left
n/flutter, and QRS duration.
FpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with
SC, small cells (cannot be reported because of privacy regulations).
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Volume 2 2020troponin only marginally improved model discrimination
for 90-day mortality.24 Our study was novel because, unlike
in other studies, we demonstrated that the prognostic value
of troponin elevation was maintained across the range of
LVEF categories.16,25 An earlier study did report an asso-
ciation between peak troponin in hospital and prognosis,
but unlike in our study in which troponins were only
captured at initial emergency presentation, elevation of this
biomarker could have occurred at any time during the
hospital stay.26 Thus, troponin elevation in this prior study
could have occurred after initial presentation and could have
been a consequence of acute hemodynamic stress.26 The
prevalence of IHFS was higher in our study than in some
population-based studies,27,28 but was consistent with
another prior study.29 This may have resulted from our
intentionally broad inclusion of mildly elevated troponin as
part of an IHFS.
The mechanisms by which troponin elevation could
confer worsened prognosis include myocyte ischemia or
injury, defect in cell membrane integrity, inflammation,
and apoptosis.30 These could be exacerbated by activation
of the renin-angiotensin-aldosterone system, adrenergic
activity, inflammatory cytokines, and mechanical or
oxidative stress.30 It is still not defined to what extent
demandesupply mismatch related to volume overload and
decompensated HF or nonischemic mechanisms may
contribute to the worsened prognosis of troponin eleva-
tion.26 In our study, angina was associated with lower risk
of death at 1 year, and this could have resulted because
those with IHFS who have manifest symptoms may enable
the detection of ischemia. This hypothesis is supported by
the CORONA, CHARM, and I-PRESERVE trials
mentioned previously because angina was associated with
increased risk of ischemic events, but not mortality.
Alternatively, the beneficial effects of anginal symptoms
may be mediated by ischemic preconditioning, including
via protein kinase C signaling pathways and downstream
effects on Akt, PI3 kinase, and ERK.31 Even brief episodes
of angina can promote ischemic preconditioning32 and
could have been responsible for the effects we observed. It
should also be noted that although a significant impact of
troponin elevation was not observed in those with elevated
troponin and HFmrEF, this was the smallest LVEF sub-
group with only 35% power to detect a multivariable HR
of 1.72.33,34 In contrast, there was 99% power to detect
this effect size in the overall HF cohort of 5353 patients.
We would anticipate that a larger number of patients with
HFmrEF would have led to a significant association of
troponin elevation with mortality.
Our findings highlight the value of troponin as an
important predictor of mortality in acute HF, with the risk
of death beginning to increase with mildly elevated
troponin. Although mortality risk was slightly higher at 30
days in those with MI-range troponin, the risks were
comparable to mildly elevated troponin at 1 year, sug-
gesting the possibility that higher intensity of acute medical
care in the former group could have attenuated outcome
differences. The heightened risk observed irrespective ofLVEF advocates for troponin testing upon presentation to
the ED.18 Ischemia testing could be considered even
among those with mildly elevated troponin, but before
doing so, further research is warranted to elucidate the
mechanisms for troponin’s role in IHFS.
Study strengths and limitations
This study has several strengths, including a large sample of
“real-world” patients with acute HF, characterised in detail and
linked to multiple administrative databases. Our study was
limited by the absence of a standard definition of IHFS. Thus,
our study was designed with a pragmatic definition of IHFS
broadly defined by the trio of troponin elevation, anginal
symptoms, and prior MI. Additionally, it is conceivable that
there is overlap between those with HF and an associated in-
crease in troponin vs those with acute MI with complicating
HF. Although similar clinically, there may be pathophysiologic
differences between these 2 conditions. Although it has been
debated whether HFmrEF is a separate entity,35 practice
guidelines differentiate it separately from HFpEF or HFrEF,36
and prior work has shown that a 10% decrement in LVEF is
associated with significantly increased risk of HF hospitaliza-
tion, cardiovascular hospitalization, and mortality.37Conclusions
Our study demonstrated the importance of IHFS in acute
decompensated HF irrespective of underlying HFrEF,
HFmrEF, or HFpEF status. Even a mildly elevated troponin
was associated with 30-day and 1-year mortality. Troponin
testing may serve as a useful tool to guide medical decision-
making in acute HF care.Funding Sources
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